Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Preprint
Data sources: ZENODO
Zenodo
Claim

miR-140-5p as Biomarker and Therapeutic Target

descriptionPublicationkeyboard_double_arrow_right Preprint Under curationPublisher:Zenodo
Authors: MedicOath Autonomous Discovery Engine;

doi: 10.5281/zenodo.19834041

miR-140-5p as Biomarker and Therapeutic Target

Abstract

MicroRNA-140-5p is dysregulated in sex chromosome aneuploidies and directly targets MECP2 and other X-linked genes involved in neurodevelopment. Developing antagomiRs or mimics to normalize miR-140-5p levels could restore proper gene dosage compensation and serve as both a diagnostic biomarker and therapeutic intervention for 48,XXYY syndrome.

Powered by OpenAIRE graph
Found an issue? Give us feedback